Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease A Scientific Statement From the American Heart Association

被引:237
作者
Wiggins, Barbara S. [1 ]
Saseen, Joseph J. [2 ]
Page, Robert L., II [2 ]
Reed, Brent N. [5 ]
Sneed, Kevin [6 ]
Kostis, John B. [3 ]
Lanfear, David [4 ]
Virani, Salim [7 ]
Morris, Pamela B. [1 ]
机构
[1] Med Univ South Carolina, Charleston, SC 29425 USA
[2] Univ Colorado Anschutz Med Campus, Aurora, CO USA
[3] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ USA
[4] Henry Ford Hosp, Detroit, MI 48202 USA
[5] Univ Maryland, Sch Pharm, College Pk, MD 20742 USA
[6] Univ S Florida, Coll Pharm, Tampa, FL USA
[7] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA
关键词
AHA Scientific Statements; anti-arrhythmic agents; anticoagulants; calcium channel blockers; cardiovascular disease; drug-related side effects and adverse reactions; fenofibrate/fenofibric acid derivatives; gemfibrozil; hydroxymethylglutaryl-CoA reductase inhibitors; immunosuppressive agents; COA REDUCTASE INHIBITORS; SIGNIFICANT PHARMACOKINETIC INTERACTION; TYPE-2; DIABETES-MELLITUS; LIPID-LOWERING DRUGS; CONCOMITANT USE; MYOCARDIAL-INFARCTION; P-GLYCOPROTEIN; PLASMA-CONCENTRATIONS; RANDOMIZED-TRIAL; HOSPITALIZED RHABDOMYOLYSIS;
D O I
10.1161/CIR.0000000000000456
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:E468 / E495
页数:28
相关论文
共 187 条
[11]   Oral anticoagulant drug interactions with statins: Case report of fluvastatin and review of the literature [J].
Andrus, MR .
PHARMACOTHERAPY, 2004, 24 (02) :285-290
[12]  
[Anonymous], 2011, AML PACK INS
[13]  
[Anonymous], 2016, RAN PACK INS
[14]  
[Anonymous], 2014, LOV MEV
[15]  
[Anonymous], 2015, SAC VALS ENTR
[16]  
[Anonymous], 2009, DIG PACK INS
[17]  
[Anonymous], LOP GEMF TABL
[18]  
[Anonymous], Summary of product characteristics - Eflexor
[19]  
[Anonymous], 2012, FLUV SOD LESC LESC 4
[20]  
[Anonymous], DRUG APPR PACK